Author
Co-Founder & Chief Marketing Officer, USA MedPremium
Kevin Claussen is Co-Founder and Chief Marketing Officer at USA MedPremium, a Florida-based pharmaceutical and medical supply distributor serving hospitals, clinics, infusion centers, and specialty pharmacies nationwide.
26 articles published
Discover how cutting-edge AI models are transforming supply chain visibility across the pharmaceutical industry, enabling real-time tracking and predictive demand forecasting for critical medications.
Discover why leading hospitals, surgery centers and clinics trust USA MedPremium. Learn about our 99.9% on-time delivery, 24/7 support, and commitment to healthcare excellence.
Explore IV fluid therapy: types of intravenous solutions, infusion techniques, and patient management in critical care. Learn how to administer fluids safely and reliably.
Preservative-free famotidine and lanthanum carbonate (Fosrenol) are intermittently constrained through 2026. A procurement guide for facility buyers: shortage drivers, DSCSA compliance, 503B fallbacks, and multi-source GI drug sourcing.
Your practice stocks the insulin — but does it stock the right pen needle gauge for every patient's device? A 2026 supply guide for medical practices, endocrinology clinics, infusion centers, and home health agencies: pen needle selection, ancillary consumables, DSCSA-compliant sourcing, and the procurement discipline that keeps diabetes care moving.
A procurement playbook for infusion centers and specialty pharmacies: how to source biologics, biosimilars, oncology injectables, IVIG, and specialty antibiotics when manufacturer allocation and API disruptions are the norm — with DSCSA-compliant sourcing and multi-manufacturer strategy.
The ACDS named benzyl alcohol the 2026 Allergen of the Year — and preservative-free IV solutions have shifted from specialty accommodation to mainstream procurement priority. A 2026 guide for hospital pharmacies, infusion centers, and 503B compounding on PF procurement strategy.
The ceftriaxone shortage has extended into 2026 with no resolution in sight. A procurement guide for outpatient facilities on multi-manufacturer sourcing, antimicrobial stewardship, DSCSA-compliant vendor vetting, and substitution protocols that hold when the primary supplier is backordered.
Branded GLP-1 demand, the compounded wind-down, and higher OSHA penalties have reset injection-supply purchasing. A 2026 procurement guide to pen needles, insulin and hypodermic syringes, safety-engineered devices, and FDA-cleared sharps containers.
A 2024 potency recall, FDA action on animal-derived thyroid products, and a consolidated generic market have reset levothyroxine procurement. A 2026 guide to multi-manufacturer sourcing, 12-strength par levels, NTI substitution risk, and DSCSA compliance.
Cardiovascular drugs are the largest U.S. prescription category — and in 2026 one of the hardest to keep on the shelf. A facility buyer’s playbook for sourcing cardiovascular and anticoagulant medications through heparin shortages, NDMA recalls, and DOAC consolidation.
Sourcing a growth hormone pen means a cold chain, a specialty pharmacy channel, and prior authorization that can take weeks. A 2026 buyer’s guide to every approved brand and device, the long-acting transition, cold chain handling, and par levels by facility type.
Building a reliable lab supply chain is harder in 2026 than any time since 2021: reagent lot-to-lot variability, cold chain, and closed-system lock-in. A procurement playbook covering the seven core supply categories, CLIA and CLSI, multi-vendor sourcing, and par levels by lab type.
The peptide compounding exemptions built on the 2024 GLP-1 shortages have expired, and FDA has shifted to coordinated enforcement against unapproved peptide channels. A 2026 guide to what changed, where the compliance exposure sits, and how to qualify a supply chain partner built to the standard your facility is held to.
The price on a peptide invoice matters less than the legal framework behind it. A 2026 buyer’s guide to 503A vs. 503B compounding — what each authorizes, where peptides and GLP-1s fall today, the DSCSA exemption most teams miss, and a pre-sourcing due-diligence checklist.
“It shipped overnight” is the most expensive assumption in healthcare procurement — speed is not a cold chain. A 2026 guide to why peptides are temperature-sensitive, the USP and FDA-label standards that govern cold-chain handling, and exactly what to require of any supplier before you trust them with refrigerated inventory.
If your clinic built a weight-loss or aesthetics program on compounded semaglutide or tirzepatide, the ground has shifted. A 2026 guide to the only defensible GLP-1 sourcing path after the compounding crackdown — what changed, the FDA-approved products, authorized-distributor buying, and the marketing claims that trigger enforcement.
Your distributor is your compliance exposure. A durable five-step procurement framework for vetting any pharmaceutical distributor before the first order and at every renewal — licensing, DSCSA chain of custody, Certificate of Analysis, third-party certifications, and gray-market red flags.
IV therapy is now a clinical service line under real regulatory scrutiny. A procurement playbook for sourcing IV products that stay reliable, protect margin, and survive a board inspection — 503A vs. 503B channels, USP <797> beyond-use dating, supply diversification, FTC-safe marketing, and DSCSA documentation.
The compounded-GLP-1 gold rush is over. The clinics still winning in 2026 built compliant support services around the drug — and IV nutrient therapy is the most natural one. How to build the program and source for it correctly: never IV the drug itself, keep every claim evidence-based, source through 503A/503B under USP <797>, and use the program for retention.
NAD+ is the highest-margin drip on most clinic menus — and the one with the widest gap between marketing hype and scientific evidence. How to add it as a premium service without inviting an FTC inquiry: state the FDA status accurately (compounded, not FDA-approved), keep claims inside the preliminary evidence, and source only pharmaceutical-grade NAD+ from a compliant 503A/503B compounder under USP <797>.
Glutathione, biotin, and vitamin C are the backbone of nearly every aesthetic IV menu — and they also carry the highest compliance risk on a med spa drip list. The FDA has issued direct warnings on all three. Here is how to build a beauty-drip menu that attracts clients and survives scrutiny: never market glutathione as skin-whitening, disclose biotin lab interference, screen before high-dose vitamin C, source injectable-grade only through 503A/503B under USP <797>, and hold every claim to the FTC evidence standard.
The IV clinics growing fastest in 2026 aren’t just opening more storefronts — they’re winning on two business models: mobile/at-home delivery and membership/subscription recurring revenue. Both change what you stock, how you source, and where your compliance risk lives. Mobile moves your sterile-storage boundary into a vehicle; membership rewards a stable core formulary and predictable, plannable inventory. Here’s what owners and procurement leads need to know before scaling either one.
Longevity is the hottest category in wellness, and your patients are already asking for it — NAD+ drips, glutathione pushes, antioxidant cocktails. The IV hydration market is on track to nearly double to roughly $5.66 billion by 2033. But the marketing has gotten ahead of the science, and regulators have noticed. The clinics that win the longevity wave in 2026 won’t be the ones making the boldest claims — they’ll be the ones offering premium protocols, sourced compliantly, and marketed in language that won’t trigger an FTC letter or a state board complaint. This is your playbook.
Most IV menus are built backwards — owners copy a competitor’s list, mark up the bag, and hope volume covers the rent. The clinics actually printing profit in 2026 engineer the menu: anchor drips that fill chairs, premium add-ons that carry the margin, and a sourcing strategy that protects both. Here’s how to model real net margin, architect a two-tier menu, price on value, capture recurring membership revenue, and source compliantly so your margin never becomes a liability.
Every fall, the phone starts ringing — patients want “something for the season,” a vitamin C drip, a B12 boost, an immune push before the holidays. Seasonal demand is one of the most reliable revenue waves in the IV business. It’s also one of the easiest ways to get a warning letter. The clinics that win seasonal demand in 2026 will capture it honestly — selling hydration, nutrient repletion, and convenience, never disease prevention. Here’s how to build a seasonal program that’s profitable and bulletproof.
